Clinical trial MK-6482 PN011
An Open-label, Randomized, Phase 3 Study of MK-6482
in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or
Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have
Progressed After Prior Anti-PD-1/L1 Therapy
in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or
Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have
Progressed After Prior Anti-PD-1/L1 Therapy
| Cancers | |
|---|---|
| Organ | Kidney |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Merck |
| EudraCT Identifier | 2020-002075-35 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04586231 |
| Last update |